Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

У Amgen сильная операционная прибыльность сочетается с заметно дорогой оценкой и высокой долговой нагрузкой, поэтому картина для инвестора скорее сдержанно-позитивная, чем безусловно бычья. P/E на уровне 24.49 выше медианы отрасли, а P/S и особенно P/B выглядят существенно завышенными относительно сектора, что ограничивает потенциал переоценки. При этом P/FCF близок к отраслевому уровню, а это означает, что рынок уже частично признаёт качество денежного потока, но не даёт большого дисконта. Маржа прибыли сильная: net margin 20.96% и operating margin 28.39% выше отраслевых ориентиров и за год в целом улучшались, что подтверждает устойчивость бизнеса. ROE очень высокий, ROA и ROI тоже выше медианы и демонстрируют восходящий тренд, то есть капитал используется эффективно. Однако столь высокий ROE в сочетании с debt/equity 5.65 и крупным long-term debt указывает, что часть доходности поддерживается левереджем, а не только операционной силой. Ликвидность выглядит приемлемо, но не комфортно: current ratio 1.26 и quick ratio 1.01 ниже типичных отраслевых уровней, поэтому запас прочности по оборотному капиталу ограничен. Выручка, EBITDA, gross profit и operating income в целом держатся на высоком уровне, но по ряду последних точек видна неравномерность, а не ускорение роста. Чистая прибыль и EPS остаются сильными, хотя последние значения EPS ниже пиковых уровней, что намекает на умеренное давление на темпы роста. Дивидендная доходность около 0.77% не выглядит ключевым драйвером инвестиционного кейса и скорее дополняет, чем определяет оценку. Собственный капитал растёт, но на фоне очень большой базы обязательств и долга это не снимает вопроса о финансовом рычаге. В итоге фундаментал Amgen поддерживает премию к слабым игрокам сектора, но высокая оценка по продажам и балансовым метрикам вместе с долговой нагрузкой ограничивают апсайд и требуют консервативного подхода к целевой цене.

Amgen Inc.

Сильный индекс, значительно упал. Быки в растерянности.

Strong index, significantly down. The bulls are confused.

Сильный индекс, значительно упал. Медведи в растерянности.

Strong index, significantly down. The bears are confused.

Средний индекс, незначительно вырос. Рынок на стороне быков.

Medium index, slightly up. The market is on the bulls' side.

Средний индекс, незначительно упал. Рынок не поддерживает медведей.

Medium index, slightly down. The market does not support the bears.

Слабый индекс, незначительно вырос

Слабый индекс, незначительно упал. Приток средств в шорты остался положительным, но снизился.

Weak index, slightly down. The inflow of funds into shorts remained positive, but decreased.

Сильная прибыльность и маржи Amgen поддерживают оценку, но высокая долговая нагрузка и дорогие мультипликаторы ограничивают потенциал роста.

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $415.7 million dollar inflow -- that's a 1.1% increase week over week in outstanding units (from 252,115,324 to 254,815,324). Among the largest underlying components of XLV, in trading today Amgen Inc (Symbol: AMGN) is down about 0.3%, Thermo Fisher Scientific Inc (Symbol: TMO) is off about 0.5%, and Gilead Sciences Inc (Symbol: GILD) is lower by about 1.1%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average:
Looking at the chart above, XLV's low point in its 52 week range is $127.96 per share, with $160.59 as the 52 week high point — that compares with a last trade of $153.52. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Further XLV Research:
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

XLV, AMGN, TMO, GILD: ETF Inflow Alert

Key Points
The company is expanding both approved and pipeline therapies.
New indications could expand the market for existing drugs.
Long-term cash flow growth could support future dividend increases.
That's significantly higher than many other blue-chip healthcare stocks, including Eli Lilly (NYSE: LLY), Johnson & Johnson (NYSE: JNJ), and Amgen (NASDAQ: AMGN), all of which yield dividends of roughly 2% or less.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
But dividends don't increase just because management wants them to. They rise because the business generates enough cash to support them.
Following the money
This week, AbbVie presented new data from its blood cancer portfolio at the European Hematology Association (EHA) Congress.
This is one of the world's largest medical conferences focused on blood cancers and disorders, bringing together thousands of physicians, researchers, pharmaceutical companies, and healthcare professionals to present new clinical trial data and discuss emerging treatments.
The reason EHA is important is that companies often use the conference to release new data on cancer drugs, particularly therapies targeting blood cancers. Positive results presented at EHA can support regulatory approvals, label expansions, partnerships, and future revenue growth. That's why AbbVie showcased its new clinical results there.
The company's most recent presentations included data on approved therapies as well as several pipeline candidates. In total, AbbVie showcased 21 presentations spanning multiple blood cancers, including chronic lymphocytic leukemia, follicular lymphoma, multiple myeloma, acute myeloid leukemia, and diffuse large B-cell lymphoma.
AbbVie generated about $61 billion in revenue during 2025, and while immunology drugs receive most of the attention, oncology remains an important contributor.
The company's oncology portfolio generated about $6.7 billion in revenue in 2025. That's not insignificant.
That revenue helps fund research and development, debt reduction, share repurchases, and dividends.
Indeed, oncology helps diversify AbbVie's business.
Diversifying the pipeline
You may remember the company's dependence on Humira.
At its peak, Humira was one of the best-selling drugs in pharmaceutical history, generating about $21 billion in annual revenue.
That concentration created a significant risk because patents eventually expire. And when Humira lost U.S. exclusivity in 2023, and biosimilar generics entered the market, Humira revenue began declining rapidly.
Management saw this challenge coming years in advance and responded by aggressively building new growth platforms across immunology, oncology, and neuroscience.
Today, drugs such as Skyrizi and Rinvoq (used to treat Crohn's disease, ulcerative colitis, and arthritis) are helping offset Humira's decline, while the company's oncology portfolio provides another important source of revenue and cash flow. The result is a much more diversified business than just a few years ago.
Today, AbbVie generates revenue across immunology, neuroscience, and oncology. That has reduced dependence on any single product and created a more resilient cash flow profile.
And that's why the EHA presentations are relevant.
AbbVie is actively expanding the use of existing drugs while advancing newer therapies that could eventually offset declines from older products. The company highlighted encouraging efficacy data across multiple studies, including late-stage programs and investigational treatments targeting difficult-to-treat blood cancers.
Of course, you can't guarantee successful drug development.
Clinical setbacks happen, and not every program succeeds. It's just part of the overall process of developing new therapies.
Still, AbbVie's oncology portfolio is no longer dependent on a single drug. The company now has multiple approved products, several late-stage opportunities, and a broader pipeline than it did just a few years ago.
Now consider that the latest clinical updates will strengthen the revenue engine supporting the dividend over the long term.
AbbVie's oncology business already generates billions of dollars annually, and management continues working to ensure that oncology remains a growth driver rather than a mature business.
That's why the company continues investing heavily in expanding existing therapies into new indications while advancing next-generation treatments for blood cancers and solid tumors.
Every successful clinical trial creates the potential for new approvals, larger patient populations, and longer revenue runways. And because cancer treatments often command premium pricing and can remain on the market for many years, successful oncology drugs can become meaningful cash-generating assets.
And ultimately, it's cash flow that pays dividends.
Should you buy stock in AbbVie right now?
Before you buy stock in AbbVie, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $442,220!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,230,114!*
Now, it’s worth noting Stock Advisor’s total average return is 926% — a market-crushing outperformance compared to 203% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of June 12, 2026.
Jeff Siegel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie, Amgen, and Eli Lilly. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

AbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend.

In early trading on Thursday, shares of Honeywell International topped the list of the day's best performing Dow Jones Industrial Average components, trading up 2.0%. Year to date, Honeywell International registers a 7.7% gain.
And the worst performing Dow component thus far on the day is Microsoft, trading down 2.1%. Microsoft is lower by about 19.5% looking at the year to date performance.
Two other components making moves today are Salesforce, trading down 2.0%, and Amgen, trading up 2.0% on the day.
VIDEO: Dow Movers: MSFT, HON
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Dow Movers: MSFT, HON

Amgen (AMGN) closed the most recent trading day at $337.50, moving -2.05% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 1.62%. Meanwhile, the Dow experienced a drop of 1.87%, and the technology-dominated Nasdaq saw a decrease of 1.98%.
Coming into today, shares of the world's largest biotech drugmaker had gained 2.46% in the past month. In that same time, the Medical sector gained 5.04%, while the S&P 500 lost 0.03%.
Analysts and investors alike will be keeping a close eye on the performance of Amgen in its upcoming earnings disclosure. In that report, analysts expect Amgen to post earnings of $5.55 per share. This would mark a year-over-year decline of 7.81%. Meanwhile, the latest consensus estimate predicts the revenue to be $9.44 billion, indicating a 2.87% increase compared to the same quarter of the previous year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $22.26 per share and revenue of $37.86 billion, indicating changes of +1.92% and +3.02%, respectively, compared to the previous year.
It is also important to note the recent changes to analyst estimates for Amgen. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.03% higher. Amgen is holding a Zacks Rank of #3 (Hold) right now.
In the context of valuation, Amgen is at present trading with a Forward P/E ratio of 15.48. This expresses a discount compared to the average Forward P/E of 21.35 of its industry.
Meanwhile, AMGN's PEG ratio is currently 3.48. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. By the end of yesterday's trading, the Medical - Biomedical and Genetics industry had an average PEG ratio of 1.51.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 155, putting it in the bottom 37% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Amgen (AMGN) Registers a Bigger Fall Than the Market: Important Facts to Note

In recent years, the pharmaceutical industry has witnessed a remarkable surge in the development of weight loss medications, particularly GLP-1 receptor agonists such as Ozempic and Wegovy. The global obesity rate has nearly tripled since 1975 and is expected to affect over half the population by 2035, per WHO and Goldman Sachs. Theglobal marketfor anti-obesity medications is expected to reach $50 billion by 2030.
As the prevalence of obesity rises, so do related chronic conditions such as diabetes, heart disease and hypertension, creating a massive market for treatments like GLP-1 drugs. Pioneering GLP-1 treatments, such as Ozempic, Wegovy and Zepbound, are now at the forefront of medical advancements in weight management.
Eli Lilly Hovers Around $1 Trillion Valuation
Eli Lilly LLY shares hit a $1 trillion market value, closing at its first record high since November. The stock has surged more than 25% since the March 30 market low and gained over 400% in the past five years, making Eli Lilly one of Wall Street’s biggest beneficiaries of the obesity-drug boom, per Yahoo Finance. Shares surged about 14% over the past one month (as of June 4, 2026).
Reta Fuels Investor Optimism
Much of the recent excitement centers on retatrutide, or “Reta,” Eli Lilly’s experimental next-generation obesity treatment.
Unlike approved drugs such as Zepbound and Mounjaro, which target two hormone pathways, Reta targets three pathways tied to appetite control, blood sugar regulation and energy use.
In the Phase 3 TRIUMPH-1 obesity trial, patients on the highest dose lost an average of 70.3 pounds, or 28.3% of body weight, over 80 weeks. More than 45% of participants lost at least 30% of their body weight, results often associated with bariatric surgery, per the same Yahoo Finance article.
GLP-1 Market Expands Beyond Obesity
Investors increasingly view GLP-1 drugs as a broader metabolic-health platform extending beyond obesity and diabetes into areas such as sleep apnea, kidney disease, cardiovascular risk, liver disease and addiction treatment.
Alongside Eli Lilly, Novo Nordisk NVO, Amgen AMGN and Viking Therapeutics VKTX remain key players in the obesity-drug race. Meanwhile, Indian pharma major Lupin bets big on India’s GLP-1 market.
The trend is also affecting industries outside healthcare, including packaged food, alcohol, restaurant and retail stocks, as investors assess how appetite-suppressing drugs may reshape consumer behavior.
Deloitte Warns of a GLP-1 “Bubble”
A new report from Deloitte suggests soaring demand for obesity and diabetes drugs may be creating a “bubble effect” within the pharmaceutical industry, as quoted on CNBC.
Returns on pharmaceutical R&D among the world’s top 20 drugmakers rose to 7% in 2025, driven largely by GLP-1-related assets. Obesity treatments now account for roughly 25% of projected late-stage pipeline sales, surpassing oncology for the first time in 16 years.
According to Deloitte, GLP-1 and obesity drugs now represent about 38% of projected commercial inflows from the 2025 late-stage pipeline. Excluding these drugs, the industry’s R&D return falls sharply to 2.9%.
The report also highlighted concentration risk, noting that only 9% of blockbuster late-stage therapies is expected to generate nearly 70% of total risk-adjusted peak sales.
AI and Health Tech Join the GLP-1 Boom
The obesity-drug trend is also driving growth in health technology. Health-tech startup Signos recently raised $20 million in funding and expanded its partnership with Dexcom, per a CNBC article.
Signos uses AI-powered glucose monitoring technology alongside Dexcom’s continuous glucose monitors to help users manage weight through personalized recommendations tied to food, sleep, stress and lifestyle habits.
ETFs to Play
Roundhill GLP-1 and Weight Loss ETF OZEM, Tema Heart & Health ETF HRTS and Amplify Weight Loss Drug & Treatment ETF THNR are some of the ETFs that should be closely tracked in light of the above-mentioned scenario.
LLY-heavy ETFs like the iShares U.S. Pharmaceuticals ETF IHE, Harbor Health Care ETF MEDI and VanEck Pharmaceutical ETF PPH should also benefit from this trend.
NVO-heavy ETFs such as the Simplify Health Care ETF PINK and PPH are also in focus. Meanwhile, Amgen-heavy ETFs like the VanEck Biotech ETF BBH and iShares Biotechnology ETF IBB should not be overlooked amid this euphoria.
Boost Your Portfolio with Our Top ETF Insights
Zacks' exclusive Fund Newsletter delivers actionable information, top news and analysis, as well as top-performing ETFs, straight to your inbox every week.
Don’t miss out on this valuable resource. It’s free!
Get it now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
iShares Biotechnology ETF (IBB): ETF Research Reports
iShares U.S. Pharmaceuticals ETF (IHE): ETF Research Reports
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market

Amgen AMGN is one of the several drug makers racing to develop an innovative weight-loss drug and take a share of the booming weight loss drug market. The global obesity drug market is projected to grow dramatically, reaching nearly $95 billion by 2030 and potentially $125 billion by 2035, according to Goldman Sachs estimates.
Amgen is developing MariTide, a GIPR/GLP-1 receptor, as a single dose in a convenient autoinjector device with a monthly and maybe less frequent dosing. This key feature differentiates it from Eli Lilly’s LLY and Novo Nordisk’s NVO popular GLP-1-based obesity drugs, Zepbound (tirzepatide) and Wegovy (semaglutide), respectively, which are weekly injections. A monthly therapy like MariTide may help reduce treatment burden for patients and improve persistence on treatment over time.
Amgen is evaluating MariTide in type II diabetes, obesity and obesity-related conditions as part of its comprehensive MARITIME phase III program. Amgen has nine global phase III studies underway with MariTide in obesity and other obesity-related conditions like obstructive sleep apnea, cardiovascular disease and heart failure. Three phase III studies of MariTide in type II diabetes will be initiated in 2026.
In clinical studies, it has shown predictable and sustained weight loss and a clinically meaningful impact on cardiometabolic parameters.
In phase II studies, MariTide resulted in up to approximately 20% average weight loss over 52 weeks without reaching a weight loss plateau in people who were obese or overweight but without type II diabetes. In patients with type II diabetes who were obese or overweight, the weight loss reduction was approximately 17% at 52 weeks.
An interesting study is a new phase III switch study that will assess patients transitioning from weekly tirzepatide or semaglutide therapy to MariTide administered once every eight weeks or once every 12 weeks. In other words, the study will evaluate switching from Zepbound and Wegovy injections given 52 times a year to a medicine that can be injected 4 or 6 times a year.
MariTide is by far Amgen's most important obesity asset. However, Amgen’s obesity pipeline also includes earlier-stage oral and injectable candidates like AMG 513 and AMG 786.
Can AMGN Take Share from LLY and NVO in the Obesity Space?
MariTide is a closely watched drug in the obesity market. However, with MariTide, Amgen is entering a market that is heavily dominated by Lilly and Novo Nordisk. LLY and NVO already have a massive first-mover advantage in the obesity space and enjoy strong brand recognition.
Moreover, to maintain their prowess in the lucrative obesity market, both Novo Nordisk and Lilly are developing several next-generation, more powerful and more convenient GLP-1–based treatments, including oral options and multi-acting candidates.
Lilly's next-generation candidate, retatrutide, has demonstrated approximately 28% weight loss in late-stage studies, significantly above MariTide's approximately 20%.
This will make it difficult for Amgen to capture rapid market share on a weight-loss efficacy basis, even with a differentiated product like MariTide. However, from another perspective, the obesity market is huge and can support multiple players, and even a modest market share could translate into billions of dollars in annual revenues. MariTide’s less frequent dosing is its biggest competitive advantage, and if successfully developed and launched, MariTide could become the preferred option for patients who value convenience and durable weight maintenance.
Competition Heating Up in the Obesity Space
While Lilly and Novo Nordisk currently dominate this space, smaller biotechs like Structure Therapeutics and Viking Therapeutics are also developing oral GLP-1 drugs for treating obesity.
Others, such as Roche, Merck, AbbVie, and, more recently, Pfizer PFE, have strengthened their obesity pipelines through licensing deals and acquisitions involving smaller biotechs. Pfizer has strengthened its obesity presence with last year’s licensing of YP05002 from YaoPharma and the acquisition of Metsera. AbbVie entered the obesity field by licensing GUB014295 from Gubra. Roche strengthened its obesity presence through the acquisition of Carmot Therapeutics and its obesity assets, such as CT-388, as well as the exclusive collaboration with Zealand Pharma.
AMGN’s Price Performance, Valuation and Estimates
Amgen’s stock has risen 5.3% so far this year compared with an increase of 4.0% for the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Amgen is reasonably priced. Going by the price/earnings ratio, the company’s shares currently trade at 15.05 forward earnings, which is lower than 17.59 for the industry. The stock is also trading above its five-year mean of 13.81.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for earnings has declined from $22.29 per share to $22.26 per share for 2026 over the past 60 days. For 2027, the consensus mark for earnings has risen from $23.43 to $23.70 per share over the same timeframe.
Image Source: Zacks Investment Research
Amgen has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Novo Nordisk A/S (NVO) : Free Stock Analysis Report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Can Amgen's MariTide Win Share in the Fast-Growing Obesity Market?

Sanofi SNY announced that the European Commission (EC) has approved the subcutaneous (under the skin or SC) formulation of its multiple myeloma (MM) drug, Sarclisa (isatuximab). This version, which can be administered through either an on-body injector (OBI) or a manual injection, is approved across all indications for which the drug’s intravenous (into the vein or IV) version is already approved in the region.
With this nod, Sarclisa becomes the first anticancer treatment to be administered through an OBI. It is also the first MM therapy to offer the flexibility of both SC OBI and manual injection administration in the European Union (EU).
This approval was expected after the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) issued a positive opinion recommending the approval of the SC formulation in March. Both the EC and CHMP decisions are supported by data from the phase III IRAKLIA study, which showed that treatment with Sarclisa SC was at least as effective as the IV version.
Sanofi is also seeking approval for the SC version in the United States, where a regulatory filing supported by the IRAKLIA study is currently under FDA review. A final decision is expected next month.
The SC formulation could provide a meaningful advantage over the IV version by reducing treatment administration time. Per Sanofi, the SC version can be delivered in approximately 13 minutes compared with up to several hours for the IV infusion. The shorter administration time may improve patient convenience, reduce the burden on healthcare providers and infusion centers, and potentially support broader adoption of the therapy.
SNY’s Stock Performance
Year to date, shares of Sanofi have declined 7% against the industry’s 4.4% growth.
Image Source: Zacks Investment Research
More on Sanofi’s Sarclisa
Sarclisa is approved in the EU across four multiple myeloma indications. In combination with Bristol Myers' BMY Pomalyst (pomalidomide) and dexamethasone, the drug is approved for adults with relapsed or refractory MM who have received at least two prior therapies, including Revlimid (lenalidomide) and a proteasome inhibitor. Sarclisa is also approved in combination with Amgen’s AMGN Kyprolis (carfilzomib) and dexamethasone for treating patients with relapsed/refractory MM (RRMM) who have received at least one prior therapy.
The SNY drug is also approved in combination with Velcade (bortezomib), Bristol Myers’ Revlimid and dexamethasone for adults with newly diagnosed MM who are ineligible for autologous stem cell transplant. This combination regimen is approved for adults with newly diagnosed MM who are eligible for autologous stem cell transplant.
Sarclisa is approved for similar indications in the United States.
Both Pomalyst and Revlimid are approved therapies in the MM space. Kyprolis is approved in combination with other drugs to treat certain RRMM patients.
SNY’s Zacks Ranks
Sanofi currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.
See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Amgen Inc. (AMGN) : Free Stock Analysis Report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Sanofi Wins EU Nod for Subcutaneous Sarclisa in Multiple Myeloma

(RTTNews) - Amgen Inc. (AMGN), a commercial-stage biotechnology company, reported new subgroup analyses from the phase 3 VESALIUS-CV trial of its PCSK9 inhibitor, Evolocumab (Repatha), for people living with high-risk diabetes and elevated LDL-C (Low-Density Lipoprotein Cholesterol) who have not had a prior heart attack or stroke.
Company Profile
Amgen includes a portfolio of approved products across oncology, inflammation, cardiovascular disease, bone health, and rare diseases, with a pipeline focused on clinical-stage candidates targeting a range of serious illnesses.
Repatha (Evolocumab)
Repatha, also known as Evolocumab, is a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). It is designed to bind circulating PCSK9, preventing it from binding to the low-density lipoprotein receptor (LDLR). This mechanism of Repatha increases LDLR availability to clear low-density lipoprotein (LDL) from the blood, thereby lowering LDL levels.
It was first approved by the U.S. Food and Drug Administration, or FDA, in 2015 and has been used since for patients globally.
In August 2025, the FDA approved expanded Repatha's indication to include adults at increased risk of major adverse cardiovascular events due to uncontrolled LDL-C. VESALIUS-CV
VESALIUS-CV is a phase 3, double-blind, randomized, placebo-controlled, global clinical trial designed to assess the impact of Repatha in lowering LDL-C on major adverse cardiovascular events (MACE) in patients at high cardiovascular risk who had no prior myocardial infarction or stroke.
The company enrolled approximately 12,000 patients with qualifying atherosclerosis (or established atherosclerotic disease) or high-risk diabetes, without prior MI or stroke.
Key Highlights
According to the phase 3 VESALIUS-CV results, from an analysis of 6,002 patients, Repatha, when administered to patients receiving statins or LDL-C-lowering therapies, reduced the risk of the composite primary endpoint of coronary heart disease death, myocardial infarction, or ischemic stroke (3-P MACE) by 29% compared with placebo.
The company further added that it reduced the risk of a second composite primary endpoint, which included ischemia-driven revascularization (4-P MACE), by 21%.
The median achieved LDL-C was 45 mg/dL in the Repatha arm compared to 106 mg/dL with the placebo.
Amgen has traded between $267.83 and $391.29 over the last year.
Amgen shares closed Friday at $349.58, up 1.15%. In the overnight market, shares are trading at $351.18, up 0.46%.
For more such biotechstock news visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Amgen Reports New VESALIUS-CV Subgroup Results For Evolocumab In High-Risk Diabetes

Key Points
This ETF's dividend yield was recently a solid 3.25%, about three times that of the S&P 500.
Its growth rate has been better than that of many dividend-focused funds.
It seems poised to hold up better than some other funds in a market downturn.
As I do now and then, I'm here to recommend an exchange-traded fund (ETF) for your consideration. (Remember that ETFs are funds that trade like stocks.) Specifically, one that's focused on dividend-paying stocks. There are many such ETFs to choose from, but it's hard for me to recommend any other one than the Schwab U.S. Dividend Equity ETF (NYSEMKT: SCHD).
Here's a look at why I like it so much.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
A glorious mix of income and growth
With dividend-focused ETFs, there's generally a trade-off between dividend income and growth. The highest-yielding ETFs tend to grow more slowly, and vice versa. The Schwab U.S. Dividend Equity ETF, though, is strong on both counts.
Its dividend yield is 3.25% (as of June 3); a look at its recent performance follows. I'm including the performance of the Vanguard S&P 500 ETF (NYSEMKT: VOO), which recently yielded merely 1.1%, too, for comparison.
Fund
3-Year Avg. Annual Return
5-Year Avg. Annual Return
10-Year Avg. Annual Return
Schwab U.S. Dividend Equity ETF
15.09%
8.50%
12.78%
Vanguard S&P 500 ETF
22.44%
14.10%
15.56%
Data source: Morningstar.com, as of June 3, 2026.
You can see that the Schwab fund, up 19% year to date, delivers less growth than the S&P 500, but not that much less, especially when compared with many other dividend-focused ETFs. Also, it kicks out almost three times the dividend income as the S&P 500.
Meanwhile, its expense ratio -- i.e., its annual fee -- is also compelling, at a mere 0.06%. That means that for every $10,000 you have invested in the fund, you'll pay only $6.
The Schwab U.S. Dividend Equity ETF tracks the Dow Jones U.S. Dividend 100 Index, which encompasses 100 stocks with a track record of paying dividends for at least 10 years. The index also demands that its components appear financially healthy, gauging factors such as cash flow to total debt and return on equity. That requirement can help it perform well, as companies on shakier financial ground may have to reduce or even suspend their dividend payments should they run into trouble.
Also, healthy and growing dividend-paying stocks tend to increase their payouts over time, which will benefit shareholders.
What's in the Schwab U.S. Dividend Equity ETF?
Here are the top 10 holdings as of June 2, along with their weighting in the fund and their recent dividend yield:
Stock
Weight in ETF
Recent Yield
Qualcomm
6.21%
1.47%
Texas Instruments
5.72%
1.84%
UnitedHealth Group
5.14%
2.46%
Coca-Cola
3.98%
2.69%
Chevron
3.95%
3.75%
Merck
3.78%
2.96%
Verizon Communications
3.68%
6.07%
ConocoPhillips
3.60%
2.82%
Procter & Gamble
3.50%
3.04%
Amgen
3.43%
2.98%
Data source: Morningstar.com, as of June 2, 2026.
These 10 holdings together make up about 43% of the ETF's value. About 18% of its assets are in consumer defensive stocks, 15% in energy stocks, and 18% in healthcare stocks. That kind of mix is appealing to me because I think there's a significant chance of a market pullback in the coming year or two. If that happens, those three sectors are likely to hold their value more than some others.
So give this dividend-focused ETF some consideration for your long-term stock portfolio, especially if you seek growth and income.
Should you buy stock in Schwab U.S. Dividend Equity ETF right now?
Before you buy stock in Schwab U.S. Dividend Equity ETF, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Schwab U.S. Dividend Equity ETF wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $443,191!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,258,838!*
Now, it’s worth noting Stock Advisor’s total average return is 941% — a market-crushing outperformance compared to 211% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of June 6, 2026.
Selena Maranjian has positions in Amgen, Procter & Gamble, Schwab U.S. Dividend Equity ETF, and Verizon Communications. The Motley Fool has positions in and recommends Amgen, Chevron, Merck, Qualcomm, Texas Instruments, and Vanguard S&P 500 ETF. The Motley Fool recommends ConocoPhillips, UnitedHealth Group, and Verizon Communications. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The Smartest Dividend ETF to Buy With $1,000 Right Now -- and It's Up 19% in 2026

Explore the exciting world of Amgen (NASDAQ: AMGN) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
*Stock prices used were the prices of April 22, 2026. The video was published on June 12, 2026.
Should you buy stock in Amgen right now?
Before you buy stock in Amgen, consider this:
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Amgen wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $439,847!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,342,065!*
Now, it’s worth noting Stock Advisor’s total average return is 968% — a market-crushing outperformance compared to 211% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of June 5, 2026.
Anand Chokkavelu has no position in any of the stocks mentioned. Karl Thiel has no position in any of the stocks mentioned. Keith Speights has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amgen. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Amgen Inc.

Options Strategies